Jiaqi Wu

Jiaqi Wu

Auto-generated profile, based on publicly available information

Jiaqi Wu

The Third School of Clinical Medicine (School of Rehabilitation Medicine), Zhejiang Chinese Medical University, Hangzhou, People’s Republic of China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
QYQintao Yu
Qintao Yu
XWXinru Wang
Xinru Wang
JWJiaqi Wu
Jiaqi Wu
QZQiyuan Zhang
Qiyuan Zhang
XYXiaoqi Ying
Xiaoqi Ying
DHDexiong Han
Dexiong Han
Introduction: Postherpetic neuralgia (PHN) is a persistent neuropathic pain condition that endures for at least 3 months following the onset of herpes zoster, significantly impairing life quality of patients. Current PHN treatments demonstrate limited efficacy, and the lack of reliable severity biomarkers hinders effective clinical management. Electroacupuncture represents a promising therapeutic approach for PHN, though comprehensive evidence supporting its efficacy and safety is still needed. Furthermore, as objective indicators, the role of serum biomarkers in assessments still requires further investigation. Methods: This multicenter, sham-controlled, randomized study will recruit 180 patients with PHN. Participants will be allocated in a 1:1:1 ratio to electroacupuncture, sham acupuncture, or waiting-list groups via multicenter stratified block randomization. Participants will receive 1-month of treatment and 3-month follow-ups. The electroacupuncture group and the sham acupuncture group will each receive 12 treatments. All participants will maintain their pre-enrollment medication. Primary outcome is Numerical Rating Scale; secondary outcomes include pain episode frequency, Hamilton Anxiety Scale, Hamilton Depression Scale, The Short-Form 36 Health Survey, and changes of biomarkers (Neuropeptide Y, Substance P, Tumor Necrosis Factor-α, Interleukin-10). A linear mixed-effects model will be used to analyze data at different time points to explore the efficacy of electroacupuncture and the correlation between serum biomarkers and pain intensity. The predictive value of biomarkers for refractory postherpetic neuralgia (NRS reduction < 30% from baseline post-treatment) will be assessed using ROC curves. Conclusion: The expected outcomes will clarify the efficacy and safety of electroacupuncture for PHN. The study will also analyze the correlation between serum biomarkers and pain symptoms and determine whether serum biomarkers can serve as prognostic indicators for refractory postherpetic neuralgia. Trial Registration: ClinicalTrials.gov identifier: NCT06990854. Registered on June 3, 2025. (https://clinicaltrials.gov/study/NCT06990854).

25 September 2026 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
JWJiaqi Wu
Jiaqi Wu
JNJiage Niu
Jiage Niu